BLAINJECTIONINJECTABLE
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REZVOGLAR is a biosimilar insulin glargine approved by the FDA in December 2021, developed by Eli Lilly as an insulin analog for diabetes management. It is a long-acting basal insulin that helps regulate blood glucose levels in patients with type 1 and type 2 diabetes. The drug works by mimicking the body's natural insulin to control blood sugar throughout the day.
Peak
As a recently approved biosimilar in peak lifecycle, REZVOGLAR teams are focused on market penetration and formulary access to compete against entrenched reference products.
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on REZVOGLAR positions you in diabetes care, one of pharma's largest markets, with exposure to biosimilar competitive dynamics and payer strategy. Roles emphasize field execution, formulary placement, and patient acquisition in a mature indication.
Brand ManagerField Sales Representative
Worked on REZVOGLAR at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.